Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging tracer could reveal how chemotherapy affects lymphoma blood vessels

NCT ID NCT02490891

Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special PET scan tracer called 18F-RGD-K5 in 21 people with lymphoma. The tracer highlights blood vessel growth (angiogenesis) in tumors. Scans were done before and after two rounds of chemotherapy to see how the tumors changed. The goal was to learn whether this imaging method can measure treatment response, not to treat the disease directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-RGD-K5 tracer
What this could lead to
If successful, this imaging method could help doctors see how well chemotherapy is working by tracking tumor blood vessel changes.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to all lymphoma patients. The tracer is experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

21 people

The number who actually took part.

Started

Nov 2015

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female * Age ≥ 18 years old * OMS ≤ 1 * Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype * Presence of measurable tumor with at least a node mass superior to 3 centimeters * Stage I to IV * Inform consent signed Exclusion Criteria: * Primary cerebral lymphoma * Absence of fixing on FDG-PET exam * Pregnant , child bearing, breast feeding or without effective contraception method woman * Hypersensitivity to RGD-K5 * Hypersensitivity to FDG * Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter) * Neoplastic disease (less than 2 years or in progression)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.